Review
Oncology
Stephanie. A. A. Berg, Bradley. A. A. McGregor
Summary: This article discusses the treatment options and methods for clear cell renal cell carcinoma after radical nephrectomy. Currently, oral vascular endothelial growth factor receptor tyrosine kinase inhibitors or intravenous immune checkpoint inhibitors are the approved treatments, although they can cause toxic reactions. Multiple clinical trials are currently underway to explore the role of adjuvant treatment after nephrectomy, and biomarkers may help determine the effectiveness of treatments for patients.
Article
Oncology
Tarini Prasad Sahoo, Chirag Desai, Shyam Agarwal, Amit Rauthan, Boman Dhabhar, Ghanshyam Biswas, Sandeep Batra, Rajat Saha, Arun Philip, Vijay Agarwal, Palanki Satya Dattatreya, P. N. Mohapatra, Chetan Deshmukh, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate
Summary: In advanced Renal Cell Carcinoma (aRCC), systemic therapy with TKIs and IOs is recommended, as surgery has little role in these patients. The sequencing of therapies is crucial in determining subsequent line therapy. However, in India, there are barriers to RCC treatment, including the high cost of immunotherapy and the consideration of disease burden in treatment decision-making. The lack of India-specific guidelines for ccRCC treatment and sequencing further complicates management. This consensus article provides valuable expert recommendations based on clinical evidence for specialists treating advanced ccRCC.
Article
Oncology
Minsun Jung, Seokhyeon Lee, Kyung Chul Moon
Summary: This study identified c-Met and EPHA7 as receptor tyrosine kinases associated with myoferlin in clear cell renal cell carcinoma (ccRCC). High expression of c-Met and EPHA7 was independently associated with poor prognosis, indicating their potential as prognostic biomarkers. The study also suggests that the myoferlin/c-Met pathway could be a novel therapeutic target in ccRCC.
Review
Oncology
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
Summary: Non-clear cell renal cell carcinoma (nccRCC) is a common subtype of renal cell carcinoma, which mainly affects younger patients and often presents with metastasis. The prognosis of nccRCC is generally worse compared to other subtypes. Clinical trials for this subtype are lacking, leading to limited data on response rates and survival outcomes. Current treatment options for nccRCC are still being investigated, often based on extrapolation from studies on clear-cell RCC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
J. Arevalo, I. Campoy, M. Duran, S. Nemours, A. Areny, M. Vall-Palomar, C. Martinez, G. Cantero-Recasens, A. Meseguer
Summary: This study demonstrates for the first time the role of overall STAT3 phosphorylation state in the development of clear cell renal cell carcinoma (ccRCC), showing that phosphorylation at serine 727 promotes the expression of specific subsets of target genes and may serve as novel biomarkers and potential therapeutic targets for ccRCC.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Yann-Alexandre Vano, Sylvain Ladoire, Reza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Berangere Narciso, Christophe Sajous, Sophie Tartas, Eric Voog, Alain Ravaud
Summary: The first-line treatment options for metastatic clear cell renal cell carcinoma have significantly increased, with a recommended therapeutic strategy based on a combination, but the choice between dual immunotherapy or immunotherapy combined with an antiangiogenic drug is not clearly standardized. Multiple phase III trials have shown the superiority of combination therapy over monotherapy, but unresolved issues include the relevance of treatment options based on the patient's profile and consideration of subsequent treatments.
Article
Oncology
Haoran Li, Kamal Kant Sahu, James Brundage, Mallory Benson, Umang Swami, Kenneth M. Boucher, Sumati Gupta, Josiah Hawks, Deepika Sirohi, Neeraj Agarwal, Benjamin L. Maughan
Summary: This phase I trial evaluated the safety and clinical activity of combined therapy with avelumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma. The results demonstrated that this combination therapy is safe and showed positive clinical responses in some patients.
Article
Oncology
Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal
Summary: This article reports on the efficacy of Tivozanib in histologically diverse non-clear cell renal cell carcinoma. The study found that Tivozanib demonstrated activity and a favorable safety profile in patients with non-clear cell renal cell carcinoma, adding to the evidence supporting the use of VEGFR-TKI in this type of cancer.
Article
Oncology
S. Aeppli, M. Schmaus, T. Eisen, B. Escudier, V Gruenwald, J. Larkin, D. McDermott, J. Oldenburg, C. Porta, B. Rini, M. Schmidinger, C. N. Sternberg, C. Rothermundt, P. M. Putora
Summary: In the first-line treatment of metastatic clear cell renal cell carcinoma, experts recommended various drugs and drug combinations based on different decision criteria and parameters, with significant inter-expert variations observed. This demonstrates how data from randomized trials are implemented differently in daily practice.
Review
Oncology
Junwei Yang, Kuansong Wang, Zhichun Yang
Summary: Clear cell renal cell carcinoma (ccRCC) is a highly prevalent and refractory type of kidney cancer with a high risk of metastasis, recurrence, and resistance to therapy. Recent research has focused on identifying risk factors and optimizing clinical treatment based on the molecular mechanisms of ccRCC. This paper reviews established clinical therapies and explores novel approaches, emphasizing the importance of investigating new therapeutic options and combining them with established therapies to address drug resistance and promote precision medicine and individualized treatment.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Tony Zibo Zhuang, Katherine Case, Timothy Anders Olsen, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Jamie Goldman, Wayne Harris, Mehmet Asim Bilen, Bassel Nazha
Summary: Renal cancer is a common malignancy and immunotherapy has become a first-line treatment for metastatic renal cell carcinoma. However, some patients still experience cancer progression during immunotherapy. This review summarizes the latest data on first-line treatments and ongoing clinical trials in the treatment of metastatic renal cell carcinomas and explores the developing treatment landscape.
Article
Biochemistry & Molecular Biology
Angela Zaccagnino, Bozhena Vynnytska-Myronovska, Michael Stoeckle, Kerstin Junker
Summary: The study found that the tyrosine kinase inhibitor cabozantinib can inhibit the growth of sunitinib-resistant cell lines in metastatic renal cell carcinoma. However, the response to cabozantinib varies among different cell lines, and the MET and AXL expression levels do not affect the responsiveness to cabozantinib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Alessandro Comandone, Federica Vana, Tiziana Comandone, Marcello Tucci
Summary: In recent years, research on the biological mechanisms and treatment of clear cell renal carcinoma has made significant progress. Neo-angiogenesis has been identified as a key player in tumor growth and metastasis, leading to the approval of antiangiogenic drugs with impressive results in treatment outcomes.
Article
Oncology
Yongchang Lai, Weizhou Wu, Xiongfa Liang, Fangling Zhong, Lingyue An, Zhenglin Chang, Chao Cai, Zhaohui He, Wenqi Wu
Summary: The study revealed a strong association between Cx43 and RTK expression and ccRCC progression. Additionally, tangeretin was found to inhibit the malignancy of RCC cells by inhibiting Cx43 expression and enhance their sensitivity to TKIs.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Caroline S. Jansen, Yujin Choi, Sean T. Evans, Rachel Greenwald, Joseph A. Behnke, Caitlin Hartman, Haydn Kissick, Lara R. Harik, Mehmet Asim Bilen
Summary: Extrarenal clear cell renal cell carcinoma (eccRCC) is a rare type of RCC that lacks established consensus guidelines for treatment. This case report demonstrates the successful use of combination therapy with IO+VEGF-TKI, which resulted in an excellent and durable response. This highlights the potential of this treatment option for eccRCC patients.
FRONTIERS IN ONCOLOGY
(2023)